Healthcare Industry News: diaDexus
News Release - October 26, 2011
Sarah Schiltz Named VP of Marketing at Atherotech Diagnostics Lab
Move strengthens management team, positions company for future growthBIRMINGHAM, Ala.--(Healthcare Sales & Marketing Network)-- Atherotech Diagnostics Lab has named Sarah Schiltz to the newly created position of vice president of marketing. Schiltz brings 25 years of marketing, sales and business development experience to the cardiodiagnostic company, including a strong background in cardiovascular disease markets.
“Sarah is a talented health care executive with a proven track record of leading growth and expansion efforts by generating market momentum,” Atherotech CEO Michael Mullen said. “Her strong combination of skills and experience represents an important addition to our management team and supports the continuing success of our growing advanced cardiovascular disease testing business and company growth initiatives.”
Schiltz has held a range of executive-level roles at industry-leading medical diagnostic companies. Most recently, she served as director of marketing and sales at diaDexus (DDXS.OB) of South San Francisco, Calif., where she successfully led strategic marketing, sales and business development for the company’s novel cardiovascular risk marker — the PLAC®Test for Lp-PLA2 — to identify individuals at increased risk of suffering a heart attack or stroke. Schiltz previously held executive marketing positions at A&D Medical of Milpitas, Calif., Cholestech Corporation (now Alere) of Hayward, Calif., and Genzyme Diagnostics of Cambridge, Mass.
Schiltz has implemented numerous successful strategic marketing and sales initiatives, product launches and partnership efforts. As vice president of marketing, she will be responsible for overseeing all corporate marketing initiatives.
Atherotech’s patented VAP Test identifies a far greater number of people at risk for heart disease than the standard cholesterol test, with direct and comprehensive measurements of cholesterol markers associated with heart disease. Atherotech Diagnostics Lab provides physicians with a single source for the VAP Test and more than a dozen cardiovascular and metabolic tests. The company provides its unique testing services to physicians, hospitals, clinics and other laboratories throughout the U.S.
For information visit www.Atherotech.com or call 877.901.8510. Atherotech Diagnostics Lab is on Twitter at www.Twitter.com/Atherotech and also on Facebook at www.Facebook.com/Atherotech.
About Atherotech Diagnostics Lab
Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company’s patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.atherotech.com.
Source: Atherotech Diagnostics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
